Circulating Tumor Cells and the CellSearch Assay
CellSearch Use in MBC Clinical Trial6
April 2011
A multicenter, prospective, longitudinal clinical trial using the CellSearch system was conducted between 2001 and 2003, and the results published in 4 scientific publications. The summary of these results can be seen in this chart. The trial included 177 patients with metastatic disease as defined by standard imaging techniques. Results were used to determine whether the number of circulating tumor cells predicted disease progression and survival in metastatic breast cancer patients. A baseline circulating tumor cell count was determined prior to start of new therapy and an initial follow-up count was determined after the start of therapy. Progression-free survival was determined from the time of the baseline draw to identifiable disease progression based on CT scans or clinical indications. Overall survival was measured from baseline blood draw to the time of death. Lets take a look at these results a little more closely on the next few slides.
CellSearch Use in MBC Clinical Trial6 |
Jump to section:
- Introduction
- Circulating Tumor Cell (CTC)
- The Metastatic Process
- Needle in a Haystack...
- Circulating Tumor Cells
- The CellSearch System (Veridex LLC)
- Automated Sample Preparation
- Labeling and Identification of CTCs
- Labeling and Identification of Cells
- Cell Analysis
- Mayo Medical Laboratories FDA-Cleared Assays
- Metastatic Breast Cancer (MBC)
- CellSearch Use in MBC Clinical Trial6
- Progression-Free Survival in MBC
- Overall Survival in MBC
- Metastatic Colorectal Cancer (MCRC)
- CellSearch Use in MCRC Clinical Trial8
- Progression-Free Survival in MCRC
- Overall Survival in MCRC
- Metastatic Prostate Cancer (MPC)
- CellSearch Use in MPC Clinical Trial8
- Progression-Free Survival in MPC
- Overall Survival in MPC
- The Future of CTC
- References
- Questions?
External
link
PDF
document
Excel
document
Word
document